Nebenwirkungen · Gazyvaro
Gazyvaro 1 000 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 20–21
HOS-129919 · Präparat HOS-096817
20 System organ class All Grades Grades 3-5† Frequency Gazyvaro + chemotherapy* Gazyvaro + chemotherapy* (CLL, iNHL) followed by (CLL, iNHL) followed by Gazyvaro maintenance (iNHL) Gazyvaro maintenance (iNHL) Uncommon Pruritus Musculoskeletal and connective tissue disorders Very common Arthralgia§, back pain, pain in extremity Common Musculoskeletal chest pain, bone Pain in extremity pain Uncommon Arthralgia, back pain, musculoskeletal chest pain, bone pain Renal and Urinary Disorders Common Dysuria, urinary incontinence Uncommon Dysuria, urinary incontinence General disorders and administration site conditions Very common Pyrexia, Asthenia, fatigue Common Chest pain Pyrexia, asthenia, fatigue Uncommon Chest pain Immune system disorders Rare Cytokine release syndrome** Investigations Common White blood cell count decreased, White blood cell count decreased, neutrophil count decreased, neutrophil count decreased weight increased Uncommon Hypogammaglobulinemia Injury, poisoning and procedural complications Very common IRRs IRRs # Only the highest frequency observed in the trials is reported (based on studies BO21004/previously untreated CLL,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T10:49:00Z · SHA-256 18e252f824981860d284b6a8d0590c4e67726398fe4cfebbac1cb10441aeb96a · Passage d94857561ae6dee1eaab2bc806ad1a488fcc9ebca8452b15b1e5c6cd10f32447 · Zeichen 7103–9500 im Abschnitt